Moreover, the confirmation that SARS-CoV-2 induces the upregulation of systemic ACE2 activity could also provide a rationale for the correlation between a high probability to develop severe forms of COVID-19 and a pre-existing high levels of circulating ACE2 that are typical of patient groups with comorbidities linked to severe COVID-19. This evidence concerns the gene ACE2 and COVID-19.